Fluconazole

證據等級: L5

預測適應症: 1 個

Using the drug-repurposing report template supplied directly in your prompt (no matching specialized skill covers this exact task — this is the report-writing instruction itself), I’ve built the report strictly from the Evidence Pack fields, omitting sections with no data per the prohibitions (no cytotoxicity section — fluconazole is antifungal, not antineoplastic; no US/TW market table — zero licenses; no fabricated original-indication text).

Fluconazole: From No TFDA-Approved Indication to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Fluconazole is a triazole antifungal agent, but no original indication list, mechanism-of-action detail, or Taiwan market license data is currently available for this candidate (the drug is recorded as not marketed in Taiwan with 0 licenses). The TxGNN model predicts possible efficacy for Punctate Epithelial Keratoconjunctivitis, with a prediction score of 99.24%, but this direction is currently supported by 0 clinical trials and 0 publications, placing it at the lowest evidence tier.

Quick Overview

Item	Content
Original Indication	Not available — no TFDA license records and empty original indication list
Predicted New Indication	Punctate Epithelial Keratoconjunctivitis
TxGNN Prediction Score	99.24%
Evidence Level	L5
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap), and no original indication list is on record for this candidate. Based on the drug class information that is available, fluconazole is a triazole antifungal, which mechanistically inhibits the fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.

The predicted new indication, punctate epithelial keratoconjunctivitis (點狀上皮性角膜結膜炎), is in most cases caused by viral infection (e.g., adenovirus-associated epidemic keratoconjunctivitis) or by dry eye/immune-mediated pathology — only a minority of cases are fungal in origin (e.g., Candida or Fusarium keratitis presenting with punctate epithelial lesions). If a given case is confirmed fungal, fluconazole’s antifungal mechanism has a plausible theoretical link to topical/systemic treatment of fungal keratitis.

However, because the disease label here does not specify a pathogen, this mechanistic link is indirect and inferential rather than a direct pathophysiological connection. This is further weakened by the absence of original MOA data, an empty original-indication list, and the drug’s unmarketed status in Taiwan — all of which reduce the overall credibility of the prediction at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA label warnings/contraindications are recorded as a Blocking data gap — this must be resolved before any S1 safety pre-assessment can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate sits at Evidence Level L5 — a TxGNN model prediction with zero supporting clinical trials or literature — and the mechanistic rationale linking fluconazole to punctate epithelial keratoconjunctivitis is indirect, since the indication’s etiology is predominantly non-fungal. The drug is also unmarketed in Taiwan (0 licenses), and a Blocking data gap on TFDA warnings/contraindications prevents any safety pre-assessment.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — Blocking gap, required before S1 safety review
Confirmed mechanism of action (MOA) data via DrugBank
Original indication history for fluconazole to assess similarity to the predicted indication
Pathogen-specific evidence (culture/PCR-confirmed fungal keratitis) supporting relevance of the predicted indication before pursuing clinical or literature searches further
Any real-world or case-level evidence of antifungal use in fungal-associated punctate keratoconjunctivitis, since current searches (ClinicalTrials.gov, ICTRP, PubMed) returned zero results
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.